SCHEMBL24254495

SCHEMBL24254495

Cc1ccc(S(=O)(=O)N(C)C)cc1NC(=O)CCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 1.00
RAB9A P51151 1/20 0.66
LMNA P02545 3/20 0.61
L3MBTL1 Q9Y468 2/20 0.58
POLB P06746 2/20 0.57
PKM P14618 1/20 0.57
MAPK14 Q16539 1/20 0.56
KMT2A Q03164 1/20 0.55
NPSR1 Q6W5P4 2/20 0.55
KDM4E B2RXH2 1/20 0.54
MAPT P10636 1/20 0.54
THRB P10828 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
GAA P10253 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254500 0.88 ALDH1A1 (0.78) ALDH1A1RAB9ALMNAL3MBTL1PKM
SCHEMBL24254509 0.81 ALDH1A1 (0.69) ALDH1A1RAB9ALMNAL3MBTL1PKM
SCHEMBL26188047 0.80 ALDH1A1 (0.67) ALDH1A1RAB9ALMNAL3MBTL1POLB
SCHEMBL23057067 0.80 ALDH1A1 (0.66) ALDH1A1RAB9ALMNAL3MBTL1POLB
SCHEMBL24254587 0.80 ALDH1A1 (0.65) ALDH1A1RAB9ALMNAL3MBTL1POLB
SCHEMBL14227348 0.78 LMNA (0.67) ALDH1A1RAB9ALMNAPOLBKDM4E
SCHEMBL26188049 0.78 ALDH1A1 (0.64) ALDH1A1RAB9ALMNAL3MBTL1PKM
SCHEMBL26188145 0.78 ALDH1A1 (0.64) ALDH1A1RAB9ALMNAL3MBTL1POLB
SCHEMBL4663028 0.77 LMNA (0.67) ALDH1A1RAB9ALMNAL3MBTL1PKM
SCHEMBL24254498 0.77 ALDH1A1 (0.63) ALDH1A1RAB9ALMNAPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 ALDH1A1 1387/4885RAB9A 1230/4885LMNA 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.